NewMoneyMoves
PerspectivesResearchTerminalsWeekend RWABoard
HomeEarningsEli Lilly and Company FY2023 Q4
Released
FY2023 Q4
Earnings Review
LLY
BEAT

Eli Lilly and Company

Eli Lilly and Company · Biotech/Pharma (Obesity)

Tue, February 6, 2024·Before Market Open
BiotechLLYEarnings

01Wall Street Consensus

EPS$2.36
Revenue$9.2B

02Earnings Results

EPS$2.49+5.5%
Revenue$9.4B+2.2%

Key Checkpoints

    Upside Catalysts

      Risk Factors

        Detail

        EEPS History (Last 12 Quarters)

        Actual EPS vs Consensus — Green Beat · Red Miss

        Beat9
        Miss3
        Beat rate75%
        Detail

        SEPS 서프라이즈 히스토리

        Beat9Miss3Beat률 75%

        분기별 EPS 컨센서스 대비 서프라이즈(%) — 막대: EPS, 점선: 매출

        컨센서스 대비 실제 EPS/매출 서프라이즈 (%)

        Comments

        Earnings
        Earnings Info
        SymbolLLY
        QuarterFY2023 Q4
        Report Date2024-02-06
        Report TimeBMO
        SectorBiotech/Pharma (Obesity)
        StatusReleased
        Wall Street Consensus
        EPS$2.36
        Revenue$9.2B
        Results
        Actual EPS$2.49
        Actual Revenue$9.4B
        NewMoneyMoves

        Global Investment through Themes

        Content

        ThemesIdeasReportsEarnings

        Explore

        GuideETFsPerspectivesTelegramNVIDIA PortfolioWeekly ReviewCredit & Leverage

        Community

        Daily News

        Legal

        Privacy PolicyTerms of ServiceDisclaimer

        © 2026 NewMoneyMoves. All rights reserved.